NCT06990984Phase 2Not yet recruiting

A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)

Study sponsor: Thiogenesis Therapeutics, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-06Estimated

Enrollment · participants18Estimated

Source updated2026-07-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-24 · 1 field changed

Primary completion date changed

− Before

~~Sep 2026~~

+ After

Jun 2027

Check registry source

Study details

Conditions studied

Leigh Syndrome

Treatments or interventions studied

TTI-0102: cysteamine-pantetheine disulfideDrug
D-MannitolDrug

Primary outcomes · main study measures

Read the study measures

measure: PK: plasma cysteamine (Tmax); description: Measurement of cysteamine in plasma: Tmax; timeFrame: Baseline (Day 1) to end of treatment (Day 84); measure: PK: plasma cysteamine (Cmax); description: Measurement of cysteamine in plasma: Cmax; timeFrame: Baseline (Day 1) to end of treatment (Day 84); measure: PK: plasma cysteamine (Cmin); description: Measurement of cysteamine in plasma: Cmin; timeFrame: Baseline (Day 1) to end of treatment (Day 84); measure: PK: plasma cysteamine (PK curve); description: Measurement of cysteamine in plasma: PK curve; timeFrame: Baseline (Day 1) to end of treatment (Day 84); measure: PK: plasma cysteamine (AUC); description: Measurement of cysteamine in plasma: AUC; timeFrame: Baseline (Day 1) to end of treatment (Day 84); measure: PD: plasma glutathione; description: Measurement of glutathione concentration in plasma; timeFrame: Baseline (Day 1) to end of treatment (Day 84)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history